Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
In Reply: Drs Rubin and Warner are concerned
that no cardiac biomarkers were used to assess time delay to presentation
for the patients with acute STEMI included in the BRAVE-2 trial. The goal
of the BRAVE 2 trial was to assess whether an invasive strategy is associated
with reduction of infarct size in patients with STEMI presenting more than
12 hours after symptom onset. The study was based on symptoms and unequivocal
electrocardiographic changes to define acute MI, and on the interval from
symptom onset to define time to presentation.
Schömig A, Ndrepepa G, Kastrati A. Mechanical Reperfusion More Than 12 Hours After Acute Myocardial Infarction—Reply. JAMA. 2005;294(16):2030-2032. doi:10.1001/jama.294.16.2031-b